tablet dosage form.

A rapid stability-indicating RP-HPLC was developed and validated for the estimation of Mirabegron and Solifenacin combination in bulk and tablet dosage form using Thermo C18 column (250 x 4.6 mm, 5m) as a stationary phase and a mixture solution of 0.1 percent Diazanium sulphate buffer: Acetonitrile (60:40 v/v) as the mobile phase at a flow rate of 1 ml/min. A photodiode array detector was used for detection at 246 nm. The linearity, sensitivity, selectivity, robustness, specificity, precision, and accuracy were all determined. The peak area response-concentration curve was rectilinear over the concentration ranges of 25-75 g/ml (Mirabegron) and 2.5-7.5 g/ml (Solifenacin), with quantitation limits of 0.793 g/ml (Mirabegron) and 0.307 g/ml (Solifenacin). The proposed method was validated for the simultaneous determination of mifepristone and misoprostol in combined tablet dosage form. In comparison to previously reported RP-HPLC methods, the performance of the proposed method was found to be rapid and cost-effective. The developed and validated stability-indicating RP-HPLC method was suitable for quality control and drug analysis.

An accurate, efficient Stability indicating reversed-phase high-perfomance liquid chromatographic (RP-HPLC) method has been developed and validated for the simultaneous estimation of Olmesartan, Cilnidipine and Chlorthalidone. All the drugs were separated on a KROMASIL 250 x 4.6 mm, column packed with 5 µm particles. The mobile phase, optimized through an experimental design, was a 45:55 (v/v) mixture of acetonitrile and Ortho phosphoric acid buffer(0.1%OPA), pumped at a flow rate of 1 ml/min. UV detection was performed at 230 nm. The retention time of Olmesartan, Cilnidipine and Chlorthalidone was found to be 2.280min, 8.356 min and 2.804min respectively. The method was validated in the sample concentration ranges of 20-120 µg/ml for Olmesartan and 5-30 µg/ml for Cilnidipine, and Chlorthalidone 6.25-37.5µg/ml.  The method demonstrated to be robust, resisting to small deliberate changes in pH and flow rate of the mobile phase. The LOD values were 0.08µg/ml, 0.04µg/ml and 0.05 µg/ml, while the LOQ values were 0.24µg/ml, 0.12µg/ml and 0.16µg/ml for Olmesartan, Cilnidipine and Chlorthalidone respectively.